- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04822649
Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition
Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients With Suspected Heart Failure With Preserved Ejection Fraction
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: So Ree Kim, MD
- Phone Number: 821094534810
- Email: soree8826kim@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Korea University Anam Hospital
-
Contact:
- So Ree Kim, MD
- Email: soree8826kim@gmail.com
-
Principal Investigator:
- Seong-Mi Park
-
Sub-Investigator:
- Mi-Na Kim
-
Sub-Investigator:
- So Ree Kim
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 20 to 80
- Typical/atypical chest pain or ischemic symptoms including dyspnea
- No significant coronary artery stenosis (>50% stenosis) in coronary angiography or computed tomography
- Left ventricular ejection fraction ≥50%
Exclusion Criteria:
- More than moderate valvular heart disease
- Congenital heart disease
- Chronic renal failure (estimated glomerular filtration rate <30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis
- Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension
- Receiving anticancer drugs
- Vasculitis associated with autoimmune diseases
- Patients with difficulty in performing exercise load evaluation (treadmill, bicycle ergometer)
- Atrial fibrillation
- Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Heart failure with preserved ejection fraction
Adenosine stress echocardiography, body composition, and cardiopulmonary exercise test will be done in all of the enrolled patients.
Left ventricular end-diastolic pressure will be assessed during coronary angiography.
|
Diagnostic test: Adenosine stress echocardiography with the evaluation of coronary artery blood flow
The color Doppler flow of distal left anterior descending artery will be examined from the modified apical four-chamber view in the anterior interventricular groove. In regard to body composition analysis, Using InBody S10, impedance is measured in 6 frequency bands (1 kilohertz (kHz), 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) for each of 5 parts (right plate, left arm, torso, right leg, left leg). Reactance is measured in 3 frequency bands (5 kHz, 50 kHz, 250 kHz for each of 5 parts (right arm, left arm, torso, right leg, left leg). By treadmill exercise test with modified Bruce protocol or bicycle ergometer for patients with orthopedic problems, maximal oxygen consumption (VO2 max) will be measured using the exhalation gas analysis.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of coronary blood flow with cardiopulmonary exercise capacity
Time Frame: up to day 14
|
Coronary blood flow is assessed by coronary flow reserve (CFR), which is defined as peak to baseline mean diastolic velocity of coronary flow. In regard to cardiopulmonary exercise capacity, maximal oxygen consumption (VO2max) will be assessed. |
up to day 14
|
Correlation of body composition with cardiopulmonary exercise capacity
Time Frame: up to day 14
|
In body composition analysis, skeletal muscle mass and body fat mass will be assessed. In regard to cardiopulmonary exercise capacity, maximal oxygen consumption (VO2max) will be assessed. |
up to day 14
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Purinergic Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine
Other Study ID Numbers
- 2020AN0030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure With Preserved Ejection Fraction (HFpEF)
-
Occlutech International ABActive, not recruitingHeart Failure With Preserved Ejection Fraction (HFpEF) | Heart Failure With Reduced Ejection Fraction (HFrEF)United States
-
University of NebraskaRecruitingHEART Camp Connect -Promoting Exercise in Adults With Heart Failure With Preserved Ejection FractionHFpEF - Heart Failure With Preserved Ejection FractionUnited States
-
Manchester University NHS Foundation TrustRecruitingHeart Failure With Preserved Ejection Fraction (HFpEF)United Kingdom
-
AstraZenecaCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States, Denmark, Italy, Canada, Korea, Republic of, Brazil, Slovakia, Japan, Bulgaria, South Africa, Sweden, Argentina
-
Novartis PharmaceuticalsTerminatedHeart Failure With Preserved Ejection Fraction (HFpEF)Japan
-
AstraZenecaParexelCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States
-
AstraZenecaCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States, Germany, Canada, Korea, Republic of, Austria, Slovakia, Australia, Bulgaria, Russian Federation, Argentina, Poland, Mexico
-
National Medical Research Center for Therapy and...RecruitingHeart Failure With Preserved Ejection Fraction (HFpEF)Russian Federation
-
Manchester University NHS Foundation TrustUniversity College, London; Sheffield Teaching Hospitals NHS Foundation Trust; University of Leicester and other collaboratorsRecruitingHeart Failure With Preserved Ejection Fraction (HFpEF)United Kingdom
-
AstraZenecaCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States
Clinical Trials on Adenosine stress echocardiography with the evaluation of coronary artery blood flow
-
Montefiore Medical CenterAmerican Heart AssociationCompletedCoronary Artery Disease | Chest Pain | Angina Pectoris | AnginaUnited States
-
Ain Shams UniversityCompletedRespiratory Distress Syndrome, NewbornEgypt
-
Minneapolis Heart Institute FoundationRecruitingPercutaneous Coronary Intervention | Target Vessel Failure in Saphenous Vein GraftsUnited States
-
Mayo ClinicNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedEndothelial Dysfunction | Coronary AtherosclerosisUnited States
-
Shizuoka Cancer CenterCompleted
-
Population Health Research InstituteCharles University, Czech Republic; Centre hospitalier de l'Université de Montréal... and other collaboratorsCompletedthe Efficacy and Safety of Off-pump CABGCanada, China, Colombia, India, Chile, Argentina, Brazil, Czech Republic, France, Italy, Poland, Turkey, United Kingdom
-
Montefiore Medical CenterAlbert Einstein College of Medicine; American Heart AssociationCompletedCoronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Unstable AnginaUnited States
-
Nantes University HospitalUnknownAcute Circulatory FailureFrance
-
Stanford UniversityRecruiting
-
University Hospital Inselspital, BerneCompleted